FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma
Recurrent Non-Hodgkin Lymphoma
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Hodgkin Lymphoma
Recurrent Adult Acute Myeloid Leukemia

Interventions: Biological: Therapeutic Allogeneic Lymphocytes

First Posted Date: 2003-09-11

Last Posted Date: 2020-01-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00068718

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇩🇪
Universitaet Leipzig, Leipzig, Germany

and more 1 locations

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Leukemia
Precancerous/Nonmalignant Condition
Small Intestine Cancer
Myelodysplastic Syndromes

First Posted Date: 2003-08-28

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00005804

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Radiation: iodine I 131 monoclonal antibody BC8
Drug: busulfan
Drug: cyclophosphamide
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: cyclosporine
Drug: methotrexate
Other: laboratory biomarker analysis

First Posted Date: 2003-07-09

Last Posted Date: 2017-08-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00005940

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Pacific Northwest National Laboratory, Richland, Washington, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

Biological Therapy in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-07-08

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00045357

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-06-20

Last Posted Date: 2010-05-13

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00025545

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Phase 1

Completed

Conditions: Myelodysplastic Syndromes
Leukemia
Myelodysplastic/Myeloproliferative Diseases
Lymphoma

First Posted Date: 2003-06-06

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00062140

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Biological Therapy in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-05-28

Last Posted Date: 2010-05-07

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00045149

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Biological Therapy in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-05-26

Last Posted Date: 2010-05-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00002786

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

Phase 2

Completed

Conditions: T-Cell Prolymphocytic Leukemia
B-Cell Prolymphocytic Leukemia
Prolymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma

Interventions: Drug: Cyclosporine
Drug: Fludarabine Phosphate
Procedure: Hematopoietic Cell Transplantation
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2003-05-07

Last Posted Date: 2017-12-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00060424

Locations: 🇺🇸
Veterans Administration Center-Seattle, Seattle, Washington, United States
🇮🇹
University of Torino, Torino, Italy
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: fludarabine phosphate
Drug: melphalan
Radiation: total-body irradiation
Drug: mycophenolate mofetil
Drug: cyclosporine
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2003-02-06

Last Posted Date: 2017-10-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00054353

Locations: 🇮🇹
University of Torino, Torino, Italy
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy